Teva Pharmaceuticals Expands Biosimilar Portfolio With Alvotech Partnership

$TEVA

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), has taken a major step in biosimilar development through its partnership with Alvotech. The U.S. Food and Drug Administration (FDA) has accepted Biologics License Applications (BLA) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®. This marks the first U.S. filing acceptance for a biosimilar to golimumab, a widely used treatment for inflammatory conditions such as rheumatoid arthritis and ankylosing spondylitis.

Alvotech’s in-house manufacturing expertise plays a crucial role in ensuring AVT05 closely mirrors the reference biologic, a key factor in biosimilar development. This partnership has already delivered two successful FDA-approved biosimilars: SIMLANDI® (adalimumab-ryvk), an interchangeable Humira® biosimilar launched in May 2024, and SELARSDI™ (ustekinumab-aekn), a Stelara® biosimilar set to enter the U.S. market in February 2025.

Biosimilars are poised to reshape the pharmaceutical landscape by providing cost-effective alternatives to high-priced biologics, expanding patient access to essential treatments. While AVT05 awaits regulatory approval, its progress signals Teva and Alvotech’s commitment to strengthening the biosimilar market. With nine biosimilars in development, Alvotech continues to position itself as a leader in the field, addressing conditions ranging from autoimmune diseases to cancer.

Teva, with a 120-year legacy and operations in 57 markets, remains at the forefront of pharmaceutical innovation. This collaboration highlights the growing importance of biosimilars in modern healthcare, offering more accessible and affordable treatment options for patients worldwide.

DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE CONSTRUED AS INVESTMENT OR MEDICAL ADVICE. CONSULT A PROFESSIONAL BEFORE MAKING ANY FINANCIAL OR HEALTHCARE DECISIONS.